NCT05836870Active, not recruitingPhase 3
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
To learn if a supervised exercise program during chemotherapy treatments can help to improve outcomes in patients who have been diagnosed with pancreatic cancer
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 58 (actual)
- First submitted
- 20 Apr 2023
- Start date
- 18 Jul 2023
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Pancreatic cancer
- NCT number
- NCT05836870
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 58
- From 18 Jul 2023 to the primary completion date, 31 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has participated in regular RT (RT for all major muscle groups at least twice per week) throughout the month prior to recruitment
Other illness
- Screen failure for exercise safety based on PAR-Q and/or PROMIS questions as described in section 4.4 (Screening Procedure).
- Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV).
- Myopathic or rheumatologic disease that impacts physical function.
Other
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Non-English speaking
- Unable to complete the baseline assessment questionnaires or functional assessments
- Recent fracture or acute musculoskeletal injury that precludes the ability to weight bear fully on all 4 limbs in order to participate in an exercise intervention.
- Numeric pain rating scale of ≥7 out of 10
- (Females only) Known pregnancy, as communicated to study personnel by clinicians in GI Medical Oncology; females of childbearing potential receive advice to use methods of contraception per usual care.
Who the study is looking for
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision of signed and dated informed consent form
- Biopsy-proven pancreatic adenocarcinoma, resectable/borderline resectable (T1-3, N0-2, M0)
- Recommended to receive 2-6 months of neoadjuvant chemotherapy followed by surgical resection including participants who have not yet received chemotherapy and participants who have already received their first cycle of chemotherapy.
- Willingness to adhere to the Tele-PancFit study intervention
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Able to schedule baseline (T0) appointment for fitness testing and program teaching at the fitness testing location at each study site or able to schedule remote fitness testing and program teaching:
- Behavioral Research and Treatment Center (BRTC) at MDACC
- Exercise Physiology laboratory in the Department of Kinesiology and Health Education at UT Austin
- Outpatient Rehabilitation gymnasium at Banner MDA
- Able to understand the description of the study, exercise program, and willing to participate
- Home or community access to wireless internet (Wi-Fi) and agreement to engage with study personnel for real-time tele-RT sessions
- Age ≥ 18
- Meet all screening requirements (described below).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.